A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy

Standard treatment of advanced biliary tract cancer (aBTC) is represented by first-line chemotherapy (CT1). However, some patients do not gain any benefit from CT1, contributing to the overall dismal prognosis of aBTC. The present study aimed to devise a prognostic model in aBTC patients receiving C...

Full description

Saved in:
Bibliographic Details
Published in:Acta oncologica 2021-10, Vol.60 (10), p.1317-1324
Main Authors: Filippi, Roberto, Montagnani, Francesco, Lombardi, Pasquale, Fornaro, Lorenzo, Aprile, Giuseppe, Casadei-Gardini, Andrea, Faloppi, Luca, Palloni, Andrea, Satolli, Maria Antonietta, Scartozzi, Mario, Citarella, Fabrizio, Lutrino, Stefania Eufemia, Vivaldi, Caterina, Silvestris, Nicola, Rovesti, Giulia, Rimini, Margherita, Aglietta, Massimo, Brandi, Giovanni, Leone, Francesco
Format: Article
Language:English
Subjects:
Advanced biliary tract neoplasms
Antineoplastic Combined Chemotherapy Protocols
Bile Duct Neoplasms
Biliary Tract Neoplasms - drug therapy
cholangiocarcinoma
gallbladder neoplasms
Humans
Lymphocytes
Prognosis
prognostic factors
prognostic score
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Standard treatment of advanced biliary tract cancer (aBTC) is represented by first-line chemotherapy (CT1). However, some patients do not gain any benefit from CT1, contributing to the overall dismal prognosis of aBTC. The present study aimed to devise a prognostic model in aBTC patients receiving CT1. A large panel of clinical, laboratory, and pathology variables, available before the start of CT1, were retrospectively assessed in a multi-centric cohort to determine their prognostic value on univariate and multivariate regression analysis. The variables that showed a significant correlation with overall survival (OS) were computed in a three-tier prognostic score. External validation of the prognostication performance was carried out. Clinical histories of 935 patients (median OS 10.3 months), with diagnosis dates ranging from 2001 to 2017, were retrieved from 14 institutions. According to multivariate analysis, Eastern Cooperative Oncology Group performance status, carbohydrate antigen 19.9, albumin levels, and neutrophil/lymphocyte ratio were strongly associated with OS (p 
ISSN:0284-186X
1651-226X
DOI:10.1080/0284186X.2021.1953704